Millipore Sigma Vibrant Logo
Attention: We have moved. EMD Millipore products are no longer available for purchase on emdmillipore.com.Learn More

530616 ACE2 Inhibitor, MLN-4760 - CAS 305335-31-3 - Calbiochem

Overview

Replacement Information

Key Specifications Table

CAS #Empirical Formula
305335-31-3C₁₉H₂₃Cl₂N₃O₄

Products

Catalog NumberPackaging Qty/Pack
5.30616.0001 Glass bottle 2 mg
Description
OverviewA cell-permeable, bioavailable, highly potent, inhibitor of angiotensin converting enzyme 2 (ACE2; IC50 = 440 pM against soluble human ACE2) that exhibits far greater selectivity over bovine bovine carboxypeptidase A and porcine ACE (IC50 = 27 and >100 µM, respectively). Binds to the active site zinc with high-affinity and emulates the transition state during peptide hydrolysis. Reduces serum and kidney ACE 2 activity and abolishes angiotensin II-induced hypertension in mice. Shown to selectively block ANG-(1-7) formation in ACE2 WT mice subjected to low ANG II concentrations (<0.1 µM), but at higher ANG II concentrations it does not affect ANG -(1-7) levels in mice.
Catalogue Number530616
Brand Family Calbiochem®
Synonyms(S,S)-2-(1-Carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)-ethylamino)-4-methylpentanoic acid, 2(S)-(1(S)-Carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)-ethylamino)-4-methylpentanoic acid, Angiotensin-Converting Enzyme-Related Carboxypeptidase Inhibitor, ML00106791, GL-1001, GL1001, MLN4760
References
ReferencesTikellis, C., et al. 2014. Am. J. Physiol. Renal Physiol. 306, F773.
Grobe, N., et al. 2013. Am. J. Physiol. Cell Physiol 304, C945.
Ye, M., et al. 2012. Hypertension 60, 730.
Dilauro, M., et al. 2010. Am. J. Physiol. Renal Physiol. 298, F1523.
Thomas, M.C., et al. 2010. Circ. Res. 107, 888.
Trask, A.J., et al. 2010. Am. J. Hypertens. 23, 687.
Byrnes, J.J., et al. 2009. Inflamm. Res. 58, 819.
Soler, M.J., et al. 2007. Kidney Int. 72, 614.
Towler, P., et al. 2004. J. Biol. Chem. 279, 17996.
Dales, N.A., et al. 2002. J. Am. Chem. Soc. 124, 11852.
Product Information
CAS number305335-31-3
FormWhite powder
Hill FormulaC₁₉H₂₃Cl₂N₃O₄
Chemical formulaC₁₉H₂₃Cl₂N₃O₄
ReversibleY
Quality LevelMQ100
Applications
Biological Information
Primary Targetsoluble human ACE2
Primary Target IC<sub>50</sub>440 pM for soluble human ACE2
Purity≥97% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalog Number GTIN
5.30616.0001 04055977260960

Documentation

ACE2 Inhibitor, MLN-4760 - CAS 305335-31-3 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

ACE2 Inhibitor, MLN-4760 - CAS 305335-31-3 - Calbiochem Certificates of Analysis

TitleLot Number
530616

References

Reference overview
Tikellis, C., et al. 2014. Am. J. Physiol. Renal Physiol. 306, F773.
Grobe, N., et al. 2013. Am. J. Physiol. Cell Physiol 304, C945.
Ye, M., et al. 2012. Hypertension 60, 730.
Dilauro, M., et al. 2010. Am. J. Physiol. Renal Physiol. 298, F1523.
Thomas, M.C., et al. 2010. Circ. Res. 107, 888.
Trask, A.J., et al. 2010. Am. J. Hypertens. 23, 687.
Byrnes, J.J., et al. 2009. Inflamm. Res. 58, 819.
Soler, M.J., et al. 2007. Kidney Int. 72, 614.
Towler, P., et al. 2004. J. Biol. Chem. 279, 17996.
Dales, N.A., et al. 2002. J. Am. Chem. Soc. 124, 11852.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision04-June-2014 JSW
Synonyms(S,S)-2-(1-Carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)-ethylamino)-4-methylpentanoic acid, 2(S)-(1(S)-Carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)-ethylamino)-4-methylpentanoic acid, Angiotensin-Converting Enzyme-Related Carboxypeptidase Inhibitor, ML00106791, GL-1001, GL1001, MLN4760
DescriptionA selective and highly potent inhibitor against ACE2 carboxypeptidase activity (IC50 = 0.44 nM against 50 pM human ACE2; [ZnCl2] = 10 µM, [MCA-APK(DNP)] = 50 µM) with little potency toward carboxypeptidase A or ACE peptidyldipeptidase activity (IC50 = 27 µM and >100 µM against 0.5 nM bovine CPDA and 1 nM porcine ACE, respectively; [Substrate] = 50 µM). Enhances TNF- (10 pg/mL) stimulated expression of proinflammatory cytokines in murine endothelial cells (1 µM using SVEC-40 line and primary aorta endothelial cultures) in vitro and is widely employed for studying ACE2 involvement in kidney, cardiovascular, and inflammatory bowel diseases via drinking water (10 mg/kg/d), i.v. (0.1 mg/kg), and s.c. (30 mg/kg/d to 300 mg/kg/12 h) injection in rats and mice in vivo. The inhibitor Leucine moiety is shown to simultaneously target ACE2 substrate S1 pocket with its isobutyl group and active site zinc via its carboxylate, while the compound′s 3,5-dichlorobenzyl group effectively occupy S1′ subsite.
FormWhite powder
Intert gas (Yes/No) Packaged under inert gas
CAS number305335-31-3
Chemical formulaC₁₉H₂₃Cl₂N₃O₄
Purity≥97% by HPLC
SolubilityDMSO (100 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Standard Handling
ReferencesTikellis, C., et al. 2014. Am. J. Physiol. Renal Physiol. 306, F773.
Grobe, N., et al. 2013. Am. J. Physiol. Cell Physiol 304, C945.
Ye, M., et al. 2012. Hypertension 60, 730.
Dilauro, M., et al. 2010. Am. J. Physiol. Renal Physiol. 298, F1523.
Thomas, M.C., et al. 2010. Circ. Res. 107, 888.
Trask, A.J., et al. 2010. Am. J. Hypertens. 23, 687.
Byrnes, J.J., et al. 2009. Inflamm. Res. 58, 819.
Soler, M.J., et al. 2007. Kidney Int. 72, 614.
Towler, P., et al. 2004. J. Biol. Chem. 279, 17996.
Dales, N.A., et al. 2002. J. Am. Chem. Soc. 124, 11852.